AI-Enhanced Molecular Modeling for Drug Development

This case study outlines the collaboration between biosimulytics and Viridien, focusing on the development of a platform designed to expedite the drug development process for biopharma companies. The primary objective of biosimulytics is to shorten the time to market for new drug compounds by simulating lead optimization, a critical and complex phase in drug development that traditionally involves extensive laboratory experiments. The patented platform developed by biosimulytics computes the most stable crystal structures, thereby making the drug development process faster, more cost-effective, and less risky. The partnership with Viridien, which serves as the exclusive Cloud partner, has enabled biosimulytics to enhance its platform through high-performance computing (HPC) Cloud and software optimization. This collaboration has positioned biosimulytics to meet user demands for rapid results while maintaining efficiency and effectiveness in drug simulations.